Kubisz et al. Journal of Medical Case Reports 2012, 6:350 http://www.jmedicalcasereports.com/content/6/1/350 with the standard practice, rFVIIa was preferred in the presented case. Conclusions We report a successful use of ITI consisting of high- dose plasma-derived FVIII rich in vWF and IVIG in a hemophilia patient with high-titer FVIII inhibitor and intron 22 inversion. The addition of IVIG did not alter the course of ITI or the patient’s condition. Consent Written informed consent was obtained from the patient’s legal guardian (mother) for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in- Chief of this journal. Abbreviations BU: Bethesda unit; CVAD: Central venous access device; FEIBA: Factor VIII inhibitor bypass activity; FVIII: Factor VIII; IT: Inhibitor titer; ITI: Immune tolerance induction; IU: International unit; IV: Intravenous; IVIG: Intravenous immunoglobulin; rFVIIa: Recombinant activated factor VII; vWF: von Willebrand factor. Competing interests All authors declare that they have no competing interests regarding this work. Authors’ contributions PK and IP conceived this case report and were responsible for the management of the patient. PH was a major contributor in writing the manuscript and reviewing the literature data. JS made substantial contributions to the interpretation of data and participated in revising the manuscript. All authors read and approved the final manuscript. Received: 18 April 2012 Accepted: 10 September 2012 Published: 11 October 2012 References 1. Green D: Factor VIII inhibitors: a 50-year perspective. Haemophilia 2011, 17:831–838. 2. Franchini M, Lippi G: Immune tolerance induction for patients with severe hemophilia A: a critical literature review. J Thromb Thrombolys 2011, 32:439–447. 3. DI Michele DM: Immune tolerance induction in haemophilia: evidence and the way forward. J Thromb Haemost 2011, 9(Suppl. 1):216–225. 4. Mauz-Korholz C, Korholz D, Gobel U: Rapid elimination of a high-titered F VIII inhibitor by high dose recombinant F VIII combined with high dose immunoglobulin infusion. Thromb Haemost 1997, 78:959. 5. Brackmann HH, Oldenburg J, Schwaab R: Immune tolerance for the treatment of factor VIII inhibitors - twenty years of the Bonn Protocol. Vox Sang 1996, 70:30–35. 6. Coppola A, Di Minno MN, Santagostino E: Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol 2010, 150:515–528. 7. DiMichele D: The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy. Haemophilia 2009, 15:320–328. 8. Kreuz W, Escuriola-Ettingshausen C, Auerswald G, Heidemann P, Kemkes- Matthes B, Schneppenheim R: Immune tolerance induction (ITI) in haemophilia A with inhibitors: the choice of concentrate affecting success. Haematologica 2001, 86(Suppl. 4):16–20. 9. Coppola A, Margaglione M, Santagostino E, Rocino A, Grandone E, Mannucci PM, Di Minno G, for the AICE PROFIT Study Group: Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance Page 4 of 4 induction of patients with severe hemophilia A and high-responding inhibitors. J Thromb Haemost 2009, 7:1809–1815. 10. Callaghan MU, Rajpurkar M, Chitlur M, Warrier I, Lusher J: Immune tolerance induction in 31 children with haemophilia A: is ITI less successful in African Americans? Haemophilia 2011, 17:483–489. 11. Di Minno G, Coppola A: A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors? Blood Transfus 2011, 9(Suppl. 2):s14–s20. 12. Santagostino E, Mancuso ME: Venous access in haemophiliac children: choice and management. Haemophilia 2010, 16(Suppl. 1):20–24. 13. Benson G, Auerswald G, Elezović I, Lambert T, Ljung R, Morfini M, Remor E, Salek SZ: Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice. Eur J Haematol 2012, 88:371–379. 14. Hay CR, DiMichele DM: The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012, 119:1335–1344. 15. Stiefel M, Pinkwart C, Haase R, Merkel N, Forsberg D, Mauz-Körholz C: Immune tolerance induction with high-dose FVIII and pulsed intravenous immunoglobulin. Hämostaseologie 2010, 30(Suppl. 1):S119–S121. doi:10.1186/1752-1947-6-350 Cite this article as: Kubisz et al.: Successful immune tolerance induction consisting of high-dose factor VIII rich in von Willebrand factor and pulsed intravenous immunoglobulin: a case report. Journal of Medical Case Reports 2012 6:350. Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color ﬁgure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit